Two posters presented by Pearl Therapeutics at the 2011 European Respiratory Society meeting show additional data from a Phase 2b study demonstrating that Pearl's glycopyrrolate (GP)/fomoterol fumarate (FF) fixed combination metered dose inhaler and its PT001 GP monotherapy MDI both provide greater inspiratory capacity than Spiriva Handihaler tiotropium dry powder … [Read more...] about Pearl Therapeutics announces positive Phase 2b results for PT003 inhaler
Medical
Phase 3 studies presented at ERS show efficacy and safety of Flutiform
According to Mundipharma, three Phase 3 studies of the Flutiform fluticasone propionate/formoterol fumarate metered dose inhaler (MDI) have demonstrated that the product "had comparable efficacy in improving the lung function and a similar safety profile to budesonide/formoterol, a licensed combination asthma therapy," "was as effective in treating asthma as … [Read more...] about Phase 3 studies presented at ERS show efficacy and safety of Flutiform
Positive Phase 2a results for Elevation’s glycopyrrolate inhalation solution
Elevation Pharmaceuticals has presented positive results from a Phase 2a study of its glycopyrrolate inhalation solution in patients with moderate to severe COPD at the European Respiratory Society (ERS) meeting in Amsterdam. If Elevation can bring the formulation, known as EP-101, to market, it would be the first long-acting muscarinic antagonist (LAMA) available for … [Read more...] about Positive Phase 2a results for Elevation’s glycopyrrolate inhalation solution
Website for AirPROM consortium launched
The European Lung Foundation has launched a website for its AirPROM consortium, a group formed "to integrate and enhance the capacities of all partners to deliver the best possible outcome for people with asthma and chronic obstructive pulmonary disease (COPD)." The AirPROM name stands for "Airway Disease Predicting Outcomes through Patient Specific Computational … [Read more...] about Website for AirPROM consortium launched
American Academy of Family Physicians calls for affordable inhalers
The Congress of Delegates of the American Academy of Family Physicians (AAFP) has approved a resolution calling for the organization "to work with public and private payers to ensure the lowest copays for at least one inhaled steroid and one short-acting, beta adrenergic inhaler in their drug formularies with any copays at the lowest tier level, and one … [Read more...] about American Academy of Family Physicians calls for affordable inhalers
Intranasal insulin shows promise for treatment of Alzheimer’s disease
According to an article published on September 12, 2011 in the Archives of Neurology, a randomized, double-blind, placebo-controlled trial has demonstrated that intranasal insulin can improve memory and the ability to perform daily functions in adults with agnestic mild cognitive impairment or Alzheimer's disease. The study is called "Study of Nasal Insulin to Fight … [Read more...] about Intranasal insulin shows promise for treatment of Alzheimer’s disease
Iran phases out CFC inhalers
On September 5, a ceremony in Tehran marked the occasion as Iran officially phased out CFC-based metered dose inhalers (MDIs) in accordance with the Montreal Protocol, becoming the first country in the Asia-Pacific region to do so. The event, attended by government officials, clinicians, and representatives of international organizations, celebrated the closing of … [Read more...] about Iran phases out CFC inhalers
A new model for vapor deposition in the lung
A group of researchers funded by the Research Institute for Fragrance Materials (RIFM) have developed a new model for vapor deposition in the lung and have published their work in an article titled "Derivation of Mass Transfer Coefficients for Transient Uptake and Tissue Disposition of Soluble and Reactive Vapors in Lung Airways," published in the June 2011 issue of … [Read more...] about A new model for vapor deposition in the lung
NEJM editorial praises move towards personalized asthma treatment
An editorial by Monica Kraft in the August 31 online version of the New England Journal of Medicine voices approval for a recent article in the journal describing a study of lebrikizumab treatment for asthma patients whose disease was not well controlled with inhaled glucocorticoids. Lebrikizumab is a monoclonal antibody to interleukin-13, and the study found an … [Read more...] about NEJM editorial praises move towards personalized asthma treatment
Latest update on acetylcysteine inhalation solution shortage
According to the FDA's latest update on the ongoing acetylcysteine inhalation solution shortage, all of American Regent/Luitpold's product is still on back order due to "manufacturing delays," and the company is still unable to estimate a release date for any inhalation solution. The company's Shirley, NY facility was shut down in April 2011 over safety concerns. … [Read more...] about Latest update on acetylcysteine inhalation solution shortage